These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28740036)

  • 1. Increased Serum 25(OH)D
    Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H
    Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
    Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
    BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
    Deane A; Constancio L; Fogelman I; Hampson G
    BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J; Brown C; Moore AEB; Min SS; Hampson G
    Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
    Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G
    Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
    Mukaiyama K; Uchiyama S; Nakamura Y; Ikegami S; Taguchi A; Kamimura M; Kato H
    Tohoku J Exp Med; 2015 Dec; 237(4):339-43. PubMed ID: 26639092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis.
    Peris P; Martínez-Ferrer A; Monegal A; Martínez de Osaba MJ; Muxi A; Guañabens N
    Bone; 2012 Jul; 51(1):54-8. PubMed ID: 22487299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
    Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
    Nakamura Y; Suzuki T; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Tohoku J Exp Med; 2017 Apr; 241(4):319-326. PubMed ID: 28458336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
    Geller JL; Hu B; Reed S; Mirocha J; Adams JS
    Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate.
    Catalano A; Morabito N; Di Stefano A; Morini E; Basile G; Faraci B; Loddo S; Ientile R; Lasco A
    J Endocrinol Invest; 2015 Aug; 38(8):859-63. PubMed ID: 25952299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
    Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
    Brady JJ; Crowley RK; Murray BF; Kilbane MT; O'Keane M; McKenna MJ
    Ir J Med Sci; 2014 Mar; 183(1):47-52. PubMed ID: 23737138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the effect of eldecalcitol and serum 25(OH)D level.
    Takano T; Kondo S; Saito H; Matsumoto T;
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():124-7. PubMed ID: 24240066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
    Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OSTEOPOROTIC FRACTURES DURING BISPHOSPHONATE DRUG HOLIDAY.
    Bindon B; Adams W; Balasubramanian N; Sandhu J; Camacho P
    Endocr Pract; 2018 Feb; 24(2):163-169. PubMed ID: 29144808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
    Mawatari T; Muraoka R; Iwamoto Y
    Osteoporos Int; 2017 Apr; 28(4):1279-1286. PubMed ID: 27900428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.